{
    "clinical_study": {
        "@rank": "151412", 
        "arm_group": [
            {
                "arm_group_label": "diphenhydramine", 
                "arm_group_type": "Active Comparator", 
                "description": "50mg dose given as two 25mg capsules"
            }, 
            {
                "arm_group_label": "cetirizine", 
                "arm_group_type": "Active Comparator", 
                "description": "10mg dose given as 1 10mg capsule and 1 placebo capsule"
            }, 
            {
                "arm_group_label": "desloratadine", 
                "arm_group_type": "Active Comparator", 
                "description": "5mg dose given as 1 5mg capsule and 1 placebo capsule"
            }, 
            {
                "arm_group_label": "placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "given as 2 placebo capsules"
            }
        ], 
        "brief_summary": {
            "textblock": "The asthmatic airway is identified and studied using inhaled agents such as histamine and\n      methacholine.  The use of antihistamines prior to the test will inhibit the test result if\n      histamine is used to cause airway constriction.  If using methacholine, this may also be\n      true depending on whether old (e.g. benadryl) or new (e.g. desloratadine) antihistamines are\n      used.  This study will look at the effect of old and new antihistamines on inhaled\n      methacholine challenge response in individuals with mild asthma."
        }, 
        "brief_title": "Anti-histamines and Methacholine Challenges.", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Asthma", 
        "condition_browse": {
            "mesh_term": "Asthma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Baseline forced expiratory volume in 1s (FEV1) of 70%  or more of predicted\n\n          -  Methacholine provocative concentration causing a 20%  fall in FEV1 16mg/ml or less\n\n          -  No respiratory infection or change in allergen exposure for 4 weeks prior to\n             screening and throughout the study\n\n          -  No significant medical co-morbidities\n\n          -  allergy\n\n        Exclusion Criteria:\n\n          -  pregnant or breastfeeding females\n\n          -  unable to withhold antihistamines, anticholinergics, long acting bronchodilators and\n             combination therapies"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "15", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 31, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01985789", 
            "org_study_id": "PHPY2013/14"
        }, 
        "intervention": [
            {
                "arm_group_label": "diphenhydramine", 
                "intervention_name": "Diphenhydramine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "cetirizine", 
                "intervention_name": "cetirizine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "desloratadine", 
                "intervention_name": "desloratadine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "placebo", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Histamine Antagonists", 
                "Diphenhydramine", 
                "Promethazine", 
                "Cetirizine", 
                "Desloratadine", 
                "Histamine H1 Antagonists", 
                "Methacholine Chloride"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "airway hyperresponsiveness", 
        "lastchanged_date": "November 8, 2013", 
        "location": {
            "contact": {
                "email": "beth.davis@usask.ca", 
                "last_name": "Beth Davis, PhD", 
                "phone": "306-966-8291"
            }, 
            "facility": {
                "address": {
                    "city": "Saskatoon", 
                    "country": "Canada", 
                    "state": "Saskatchewan", 
                    "zip": "S7N 0W8"
                }, 
                "name": "University of Saskatchewan"
            }, 
            "investigator": {
                "last_name": "Beth E Davis, PhD", 
                "role": "Sub-Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "4", 
        "official_title": "The Effect of Antihistamines on Methacholine Challenge Testing in Asthma Patients", 
        "overall_contact": {
            "email": "beth.davis@usask.ca", 
            "last_name": "Beth Davis, PhD", 
            "phone": "306-966-8291"
        }, 
        "overall_official": {
            "affiliation": "University of Saskatchewan, Department of Medicine, Division of Respirology, Critical Care and Sleep Medicine", 
            "last_name": "Donald W Cockcroft, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Canada: Health Canada", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "change in methacholine pc20", 
            "safety_issue": "No", 
            "time_frame": "change from baseline (pre dose) at 2 hours (post dose)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01985789"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Saskatchewan", 
            "investigator_full_name": "Don Cockcroft", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "source": "University of Saskatchewan", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Don Cockcroft", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}